Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
303.50B
Market cap303.50B
Price-Earnings ratio
16.79
Price-Earnings ratio16.79
Dividend yield
2.68%
Dividend yield2.68%
Average volume
11.16M
Average volume11.16M
High today
$122.69
High today$122.69
Low today
$120.60
Low today$120.60
Open price
$122.64
Open price$122.64
Volume
9.42M
Volume9.42M
52 Week high
$123.33
52 Week high$123.33
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 303.5B, Merck(MRK) trades at $122.26. The stock has a price-to-earnings ratio of 16.79 and currently yields dividends of 2.7%.

As of 2026-02-22, Merck(MRK) stock has fluctuated between $120.60 and $122.69. The current price stands at $122.26, placing the stock +1.4% above today's low and -0.4% off the high.

The Merck(MRK)'s current trading volume is 9.42M, compared to an average daily volume of 11.16M.

In the last year, Merck(MRK) shares hit a 52-week high of $123.33 and a 52-week low of $73.31.

In the last year, Merck(MRK) shares hit a 52-week high of $123.33 and a 52-week low of $73.31.

MRK News

TipRanks 3d
Merck initiated with an Overweight at Barclays

Barclays initiated coverage of Merck (MRK) with an Overweight rating and $140 price target The firm says the company’s 2026 will bring “first-in-class” launches...

TipRanks 3d
‘An Important Potential New Option:’ Merck Stock Slides despite Successful RSV Trial

Drugmaker Merck & Company’s (MRK) shares edged lower in Thursday’s pre-market trading despite reporting positive results from its late-stage SMART clinical tria...

Simply Wall St 4d
Merck Mayo AI Partnership Aims To Sharpen Drug Discovery Decisions

Merck (NYSE:MRK) and Mayo Clinic announced a new research and development partnership focused on using artificial intelligence and multimodal clinical data for...

Merck Mayo AI Partnership Aims To Sharpen Drug Discovery Decisions

Analyst ratings

60%

of 30 ratings
Buy
60%
Hold
40%
Sell
0%

More MRK News

TipRanks 5d
Merck announces Health Canada approval of KEYTRUDA SC

Merck (MRK) announced that Health Canada has approved KEYTRUDA SC, a new subcutaneous formulation of pembrolizumab, Merck’s anti-PD-1 therapy. The approval is b...

Simply Wall St 6d
Is Merck’s First PD-1 Ovarian Cancer Approval Reshaping The Investment Case For Merck?

In early February 2026, Merck received FDA approval for KEYTRUDA and KEYTRUDA QLEX plus paclitaxel, with or without bevacizumab, for adults with PD-L1 positive,...

Is Merck’s First PD-1 Ovarian Cancer Approval Reshaping The Investment Case For Merck?

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.